Erratum: LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model (Molecular Therapy - Nucleic Acids (2017) 8 (508–519), (S2162253117302287), (10.1016/j.omtn.2017.08.002));LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model

Molecular Therapy Nucleic Acids

Volumn 8, Issue , 2017, Pages 508-519

  Zhao, Hien Tran ^a   John, Neena ^b   Delic, Vedad ^b   Ikeda Lee, Karli ^a   Kim, Aneeza ^a   Weihofen, Andreas ^c   Swayze, Eric E ^a   Kordasiewicz, Holly B ^a   West, Andrew B ^b   Volpicelli Daley, Laura A ^b  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIOGEN   (United States)

Author keywords

antisense oligonucleotides; LRRK2; Parkinson's disease; preformed fibrils; synuclein

Indexed keywords

ALPHA SYNUCLEIN; ANTISENSE OLIGONUCLEOTIDE; LEUCINE RICH REPEAT KINASE 2; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENDOSOME; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PROXIMAL TUBULE; LATERAL BRAIN VENTRICLE; LUNG ALVEOLUS CELL; LYSOSOME; MESENCEPHALON; MOUSE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SH-SY5Y CELL LINE; SINGLE DRUG DOSE;

EID: 85029310621     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1016/j.omtn.2021.05.013     Document Type: Erratum

References (55)

1. Trojanowski, J.Q., Lee, V.M., Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 55 (1998), 151–152.
2. Paisàn-Ruìz, C., Sàenz, A., Lòpez de Munain, A., Martì, I., Martìnez Gil, A., Martì-Massò, J.F., Pèrez-Tur, J., Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann. Neurol. 57 (2005), 365–372.
3. Zabetian, C.P., Samii, A., Mosley, A.D., Roberts, J.W., Leis, B.C., Yearout, D., Raskind, W.H., Griffith, A., A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005), 741–744.
4. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004), 601–607.
5. Liu, G., Aliaga, L., Cai, H., α-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol. 7 (2012), 145–153.
6. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., Dawson, T.M., Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102 (2005), 16842–16847.
7. Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. eLife, 5, 2016, e12813.
8. West, A.B., Cookson, M.R., Identification of bona-fide LRRK2 kinase substrates. Mov. Disord. 31 (2016), 1140–1141.
9. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L., Dawson, T.M., Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16 (2007), 223–232.
10. Daher, J.P., Abdelmotilib, H.A., Hu, X., Volpicelli-Daley, L.A., Moehle, M.S., Fraser, K.B., Needle, E., Chen, Y., Steyn, S.J., Galatsis, P., et al. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration. J. Biol. Chem. 290 (2015), 19433–19444.
11. Fuji, R.N., Flagella, M., Baca, M., Baptista, M.A., Brodbeck, J., Chan, B.K., Fiske, B.K., Honigberg, L., Jubb, A.M., Katavolos, P., et al. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med., 7, 2015, 273ra15.
12. Baptista, M.A., Dave, K.D., Frasier, M.A., Sherer, T.B., Greeley, M., Beck, M.J., Varsho, J.S., Parker, G.A., Moore, C., Churchill, M.J., et al. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS ONE, 8, 2013, e80705.
13. Single and Multiple Dose Study of BIIB067 in Adults with Amyotrophic Lateral Sclerosis (ALS). https://ClinicalTrials.gov/show/NCT02623699.
14. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients with Early Manifest Huntington's Disease. https://ClinicalTrials.gov/show/NCT02519036.
15. An Open-Label Safety, Tolerability, and Dose-Range Finding Study of Nusinersen (ISIS 396443) in Participants with Spinal Muscular Atrophy (SMA) (SMNRx). https://ClinicalTrials.gov/show/NCT01494701.
16. An Open-Label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants with Spinal Muscular Atrophy. https://ClinicalTrials.gov/show/NCT01703988.
17. An Open-Label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants with Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701). https://ClinicalTrials.gov/show/NCT01780246.
18. An Open-Label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants with Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246). https://ClinicalTrials.gov/show/NCT02052791.
19. A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants with Spinal Muscular Atrophy (SMA). https://ClinicalTrials.gov/show/NCT01839656.
20. A Study for Participants with Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE). https://ClinicalTrials.gov/show/NCT02594124.
21. A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants with Spinal Muscular Atrophy (SMA) (EMBRACE). https://ClinicalTrials.gov/show/NCT02462759.
22. A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NUTURE). https://ClinicalTrials.gov/show/NCT02386553.
23. Expanded Access Program (EAP) for Nusinersen in Participants with Infantile-Onset (Consistent with Type 1) Spinal Muscular Atrophy (SMA). https://ClinicalTrials.gov/show/NCT02865109.
24. A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants with Later-Onset Spinal Muscular Atrophy (SMA) (CHERISH). https://ClinicalTrials.gov/show/NCT02292537.
25. Cerritelli, S.M., Crouch, R.J., Ribonuclease H: the enzymes in eukaryotes. FEBS J. 276 (2009), 1494–1505.
26. Bennett, C.F., Baker, B.F., Pham, N., Swayze, E., Geary, R.S., Pharmacology of antisense drugs. Annu. Rev. Pharmacol. Toxicol. 57 (2017), 81–105.
27. Hung, G., Xiao, X., Peralta, R., Bhattacharjee, G., Murray, S., Norris, D., Guo, S., Monia, B.P., Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 23 (2013), 369–378.
28. Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E.V., Mazur, C., McAlonis, M.M., Pytel, K.A., Artates, J.W., Weiss, A., Cheng, S.H., Shihabuddin, L.S., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74 (2012), 1031–1044.
29. Rigo, F., Chun, S.J., Norris, D.A., Hung, G., Lee, S., Matson, J., Fey, R.A., Gaus, H., Hua, Y., Grundy, J.S., et al. Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350 (2014), 46–55.
30. Volpicelli-Daley, L.A., Abdelmotilib, H., Liu, Z., Stoyka, L., Daher, J.P., Milnerwood, A.J., Unni, V.K., Hirst, W.D., Yue, Z., Zhao, H.T., et al. G2019S-LRRK2 expression augments α-synuclein sequestration into inclusions in neurons. J. Neurosci. 36 (2016), 7415–7427.
31. Tran, H.T., Chung, C.H., Iba, M., Zhang, B., Trojanowski, J.Q., Luk, K.C., Lee, V.M., A-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. 7 (2014), 2054–2065.
32. Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A., Meaney, D.F., Trojanowski, J.Q., Lee, V.M., Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72 (2011), 57–71.
33. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner, S., et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet. 20 (2011), 4209–4223.
34. Hinkle, K.M., Yue, M., Behrouz, B., Dächsel, J.C., Lincoln, S.J., Bowles, E.E., Beevers, J.E., Dugger, B., Winner, B., Prots, I., et al. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener., 7, 2012, 25.
35. Tong, Y., Giaime, E., Yamaguchi, H., Ichimura, T., Liu, Y., Si, H., Cai, H., Bonventre, J.V., Shen, J., Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol. Neurodegener., 7, 2012, 2.
36. Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q., Lee, V.M., Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 (2012), 949–953.
37. Mao, X., Ou, M.T., Karuppagounder, S.S., Kam, T.I., Yin, X., Xiong, Y., Ge, P., Umanah, G.E., Brahmachari, S., Shin, J.H., et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 353, 2016, aah3374.
38. Paumier, K.L., Luk, K.C., Manfredsson, F.P., Kanaan, N.M., Lipton, J.W., Collier, T.J., Steece-Collier, K., Kemp, C.J., Celano, S., Schulz, E., et al. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol. Dis. 82 (2015), 185–199.
39. Abdelmotilib, H., Maltbie, T., Delic, V., Liu, Z., Hu, X., Fraser, K.B., Moehle, M.S., Stoyka, L., Anabtawi, N., Krendelchtchikova, V., et al. α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic neurodegeneration. Neurobiol. Dis. 105 (2017), 84–98.
40. Hardy, J., Cai, H., Cookson, M.R., Gwinn-Hardy, K., Singleton, A., Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60 (2006), 389–398.
41. Fraser, K.B., Moehle, M.S., Alcalay, R.N., West, A.B., LRRK2 Cohort Consortium. Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology 86 (2016), 994–999.
42. Fraser, K.B., Rawlins, A.B., Clark, R.G., Alcalay, R.N., Standaert, D.G., Liu, N., West, A.B., Parkinson's Disease Biomarker Program Consortium. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Mov. Disord. 31 (2016), 1543–1550.
43. Guerreiro, P.S., Huang, Y., Gysbers, A., Cheng, D., Gai, W.P., Outeiro, T.F., Halliday, G.M., LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models. J. Mol. Med. (Berl.) 91 (2013), 513–522.
44. Speidel, A., Felk, S., Reinhardt, P., Sterneckert, J., Gillardon, F., Leucine-rich repeat kinase 2 influences fate decision of human monocytes differentiated from induced pluripotent stem cells. PLoS ONE, 11, 2016, e0165949.
45. Thévenet, J., Pescini Gobert, R., Hooft van Huijsduijnen, R., Wiessner, C., Sagot, Y.J., Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE, 6, 2011, e21519.
46. Daher, J.P., Pletnikova, O., Biskup, S., Musso, A., Gellhaar, S., Galter, D., Troncoso, J.C., Lee, M.K., Dawson, T.M., Dawson, V.L., Moore, D.J., Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum. Mol. Genet. 21 (2012), 2420–2431.
47. Lin, X., Parisiadou, L., Gu, X.L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.X., Yang, W.J., Ding, J., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64 (2009), 807–827.
48. Daher, J.P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S., West, A.B., Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. USA 111 (2014), 9289–9294.
49. Skibinski, G., Nakamura, K., Cookson, M.R., Finkbeiner, S., Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J. Neurosci. 34 (2014), 418–433.
50. Westerlund, M., Ran, C., Borgkvist, A., Sterky, F.H., Lindqvist, E., Lundströmer, K., Pernold, K., Brené, S., Kallunki, P., Fisone, G., et al. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol. Cell. Neurosci. 39 (2008), 586–591.
51. Rudenko, I.N., Cookson, M.R., Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics 11 (2014), 738–750.
52. Orenstein, S.J., Kuo, S.H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L.S., Dauer, W., Consiglio, A., et al. Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16 (2013), 394–406.
53. Swayze, E.E., Siwkowski, A.M., Wancewicz, E.V., Migawa, M.T., Wyrzykiewicz, T.K., Hung, G., Monia, B.P., Bennett, C.F., Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35 (2007), 687–700.
54. Rigo, F., Seth, P.P., Bennett, C.F., Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv. Exp. Med. Biol. 825 (2014), 303–352.
55. Volpicelli-Daley, L.A., Luk, K.C., Lee, V.M., Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9 (2014), 2135–2146.